

# Catalyst-free, one-pot, three-component synthesis of 5-amino-1,3-aryl-1*H*-pyrazole-4-carbonitriles in green media

Alireza Hasaninejad · Somayeh Firooz

Received: 15 March 2013 / Accepted: 9 April 2013 / Published online: 27 April 2013  
© Springer Science+Business Media Dordrecht 2013

**Abstract** An efficient, one-pot, three-component synthesis of various biologically important heterocyclic compounds is described via a tandem Knoevenagel-cyclo condensation reaction of aromatic aldehydes, malono derivatives, and phenyl hydrazine derivatives in water and ethanol at room temperature.

**Keywords** Multi-component reactions · MCRs · Catalyst-free · Pyrazole · 5-Amino pyrazole · Green chemistry

## Introduction

Nitrogen-linked heterocyclic compounds have received considerable attention in recent times due to their wide applications. The cyclization reaction of suitable linear compounds is one of the most common and popular methods for preparing these heterocyclic compounds [1–7]. Between these aza containing heterocyclic compounds, pyrazoles have a long history of application in agrochemical and pharmaceutical industries [8,9]. These compounds are known to display anti-tumor [10,11], anti-bacterial [12–14], anti-microbial [15–19], anti-fungal [20], anti-inflammatory [21,22], analgesic [23,24], anti-depressant [25], anti-convulsant [26], anti-pyretic activities [27], anti-parasitic [28,29], anti-malarial [30], anti-tumor [31], and anti-viral activities [32,33]. It is well-known that the study of pyrazole derivatives is significant in pesticide chemistry, because of their

herbicidal [34,35], and insecticidal activities [36]. Moreover, applications of pyrazole containing compounds as ligands in coordination chemistry are well-documented in the literature [37,38]. A previous investigation revealed that 5-amino-4-cyanopyrazole derivatives have anti-bacterial activity [39,40]. The pyrazole motif makes the core structure of blockbuster drugs such as Celebrex(R) [41] and Viagra(R) [42] that act as PDE-5 inhibitors, Zoniporide [43] as sodium hydrogen ion exchanger inhibitors, 1-aryl-5-aminopyrazole as NPY5 antagonist [44], and PNU-32945 as HIV-reverse transcriptase inhibitors [45] (Fig. 1).



Many synthetic methods are available for the synthesis of pyrazole derivatives [46–50]. The most popular methods for the preparation of 1,3,4,5-tetrasubstituted pyrazoles are the reactions between 1,3-difunctional compounds with hydrazine derivatives (Scheme 1a) [51], 1,3-dipolar cycloadditions of diazo compounds onto triple bonds (Scheme 1b) [52,53] and the oxidative N–N bond formation of enamines and nitriles (Scheme 1c) [54]. Another used approach is the functionalization of preformed trisubstituted pyrazoles by either nucleophilic substitution or transition metal catalyzed C–N bond formation (Scheme 1d) [55–60]. A survey of the literature shows that the majority of the strategies involve either multistep sequences, or expensive catalysts, inert atmosphere, anhydrous conditions, lengthy reaction times, and laborious workup.

It is well-known that nitriles are widely used as intermediates for a large number of heterocyclic compounds [61,62]. In continuation of our research interest in the synthesis of biologically important heterocyclic compounds, we have synthesized a series of new pyrazole derivatives via a tandem Knoevenagel cyclo-condensation reaction of aromatic aldehydes, malono derivatives, and phenyl hydrazinium chloride derivatives, in water and ethanol at room temperature (Scheme 2).


**Electronic supplementary material** The online version of this article (doi:10.1007/s11030-013-9445-y) contains supplementary material, which is available to authorized users.

A. Hasaninejad (✉) · S. Firooz  
Department of Chemistry, Faculty of Sciences, Persian Gulf University,  
75169 Bushehr, Iran  
e-mail: a\_hasaninejad@yahoo.com

**Fig. 1** Biological active compounds based on pyrazole derivatives



**Scheme 1** Approaches to polysubstituted pyrazoles



**Scheme 2** Synthesis of poly-substituted amino pyrazoles

## Results and discussion

To find the optimized reaction conditions, we initiated a catalyst screening exercise employing benzaldehyde (1 mmol), malononitrile (1 mmol), and phenylhydrazine (1 mmol) in the presence of various base catalysts such as  $\text{Et}_3\text{N}$ , DABCO, DBU, NaOH, and  $\text{K}_2\text{CO}_3$  at room temperature. Screening of the reaction conditions established that the nature of the catalyst had no significant effect on the yield of pyra-

zole. Interestingly, in the absence of any base catalyst, this three-component coupling cyclization reaction proceeded smoothly to afford the desired 5-amino-4-cyano 1,3 diphenyl pyrazole in excellent yield after 30 min at room temperature in the mixture of water and ethanol (1:1 v/v) as solvent. Therefore, the phenylhydrazine itself is acting as both a Brønsted base catalyst in this reaction and as a nucleophile. This is why the bases had no effect on the reaction yield. Hence, we monitored the effect of the amount of phenylhydrazine on the yield of reaction. With a higher amount of phenylhydrazine no increase in the yield of 5-amino-4-cyano 1,3 diphenyl pyrazole is observed. However, diminishing the amount of phenylhydrazine resulted in incomplete conversion.

With these optimized conditions in hand, this three-component reaction can be readily diversified through a combination of a range of aryl aldehydes, malono derivatives, and phenylhydrazine derivatives. Among the malono derivatives, malononitrile afforded excellent yields of products (Table 1, entries 1–17). Remarkably, low nucleophilic malono derivatives also gave products (Table 1, entries 21–24) in excellent yields. Similarly, dialdehydes were also successfully employed to give bis poly-substituted pyrazoles in excellent yields (Table 1, entries 18–20).

To explore the generality of the reaction, aldehydes with electron-withdrawing substituents on aromatic ring were also employed (Table 1, entries 5, 6, 7, 8, 23). It is worth mentioning that sterically bulky aldehydes were readily converted into the desired products (Table 1, entries 3, 7). To further expand the scope of the reaction, the use of heteroaryl aldehydes was investigated (Table 1, entries 11, 12).

Some aliphatic aldehydes were also screened to carry out the three-component coupling by this method and the results

**Table 1** Synthesis of 5-amino-4-cyano 1,3-diaryl-1*H*-pyrazole derivatives

Entry	R	X	Ar'	Product	Time (h)	Yield <sup>a</sup> (%)
1	C <sub>6</sub> H <sub>5</sub>	CN	C <sub>6</sub> H <sub>5</sub>		0.50	95
2	4-Me-C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		0.65	88
3	2-OH-C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		1.30	96
4	4-Cl-C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		0.75	92
5	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		0.35	98
6	3-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		0.40	96
7	2-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		0.30	95
8	4-CN-C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		0.65	90
9	4-isopropyl-C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		1.50	78
10	3,4-di-MeO-C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		8.00	73
11	2-thienyl	CN	C <sub>6</sub> H <sub>5</sub>		1.75	88
12	5-Me-2-thienyl	CN	C <sub>6</sub> H <sub>5</sub>		2.00	90


**Table 1** continued

Entry	R	X	Ar'	Product	Time (h)	Yield <sup>a</sup> (%)
13	2-naphthyl	CN	C <sub>6</sub> H <sub>5</sub>		3.00	93
14	C <sub>6</sub> H <sub>5</sub>	CN	4-Cl-C <sub>6</sub> H <sub>4</sub>		1.00	89
15	C <sub>6</sub> H <sub>5</sub>	CN	4-Br-C <sub>6</sub> H <sub>4</sub>		0.75	89
16	1-naphthyl	CN	4-Br-C <sub>6</sub> H <sub>4</sub>		3.00	90
17	4-EtO-C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		0.75	86
18	4-OHC-C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		0.65	95
19	3-OHC-C <sub>6</sub> H <sub>4</sub>	CN	C <sub>6</sub> H <sub>5</sub>		0.80	92
20	4-OHC-C <sub>6</sub> H <sub>4</sub>	CO <sub>2</sub> Et	C <sub>6</sub> H <sub>5</sub>		2.00	87
21	C <sub>6</sub> H <sub>5</sub>	CO <sub>2</sub> M <sub>e</sub>	C <sub>6</sub> H <sub>5</sub>		1.50	93
22	C <sub>6</sub> H <sub>5</sub>	CO <sub>2</sub> Et	C <sub>6</sub> H <sub>5</sub>		1.50	95
23	4-NO <sub>2</sub> -C <sub>6</sub> H <sub>4</sub>	CO <sub>2</sub> M <sub>e</sub>	C <sub>6</sub> H <sub>5</sub>		1.00	95
24	CH <sub>3</sub> CH <sub>2</sub> CH <sub>2</sub>	CN	C <sub>6</sub> H <sub>5</sub>	—	15	—
25	(CH <sub>3</sub> ) <sub>2</sub> CH	CN	C <sub>6</sub> H <sub>5</sub>	—	15	—

<sup>a</sup> Isolated yields

are listed in Table 1. However, no products were obtained when aliphatic aldehydes were involved in this one-pot room temperature catalyst-free reaction (Table 1, entries 24, 25).


The trend observed due chiefly to the lower reactivity of aliphatic aldehydes toward nucleophilic addition in comparison with aromatic aldehydes.



**Scheme 3** Proposed mechanism for the synthesis of poly-substituted amino pyrazoles

The selectivity in the synthesis of 5-amino-1,3-aryl-1-*H*-pyrazole-4-carbonitriles can be explained by the strict sequence of the reactions shown in Scheme 3. On the basis of this suggested mechanism, olefin (**4**) readily prepares *in situ* from Knoevenagel condensation of aromatic aldehyde (**1**) with a highly reactive malono derivative (**2**). Phenylhydrazine derivative (**3**), to be able to react easily with olefin (**4**) and to eventually give rise to the formation of intermediate (**5**), which then causes the inner molecular ring to be formed after a tautomeric proton shift to produce 2,3-dihydropyrazole derivative (**7**). Finally, atmospheric oxygen acts as an oxidant to convert 2,3-dihydropyrazole derivative to the corresponding pyrazole (**8**). In this study, we did not see any dependence of reaction time and yield to the order of addition of reactants to the reaction mixture. Therefore, another plausible mechanism can be possible for the formation of imine (**6**) from the reaction of aryl aldehyde (**1**) with phenylhydrazine derivative (**3**). Malono derivative (**2**), to be able to react with imine (**6**) to give rise to the formation of intermediate (**5**) that finally converts to pyrazole (**8**) (Scheme 3).

There are various reports in the literature that pyrazole to be formed through the oxidation of initially formed dihydropyrazole (pyrazoline), using atmospheric oxygen as oxidant (the reaction was run in air) [63] or nickel peroxide or manganese dioxide or DDQ in benzene [64–66] served as the oxidant for this transformation. However, because of the difficulties of the separation of pyrazoline intermediate even under an inert atmosphere, we selected isatin (an active ketone) as a model to clarify that this reaction proceed through the pyrazoline intermediate. The reaction of isatin (**9**) with malononitrile (**2**) and phenylhydrazine (**3**)



**Scheme 4** Synthesis of 5'-Amino-2-oxo-1'-phenyl-1',2'-dihydrospiro[indoline-3,3'-pyrazole]-4-carbonitrile from the reaction of isatin malononitrile and phenylhydrazine

yielded a spirosystem with 2-oxoindole and pyrazoline fragment (**10**). The first stage of the reaction potentially follows a classic mechanism of a nucleophilic attack of the malononitrile in position C3 on isatin through the formation of 2-(2-oxoindolin-3-ylidene)malononitrile followed by Michael addition of phenylhydrazine and then intramolecular cyclization with tautomerization to 5'-amino-2-oxo-1'-phenyl-1',2'-dihydrospiro[indoline-3,3'-pyrazole]-4-carbonitrile (Scheme 4).

Thus, from a practical point of view, the newly developed protocol is a significant proof of the fact that nitrile is one of the most versatile functional groups as it can be readily transformed into various other functional groups. Significantly, the reaction occurred in a catalyst-free fashion with high selectivity and atom economy. To our knowledge, the use of catalyst-free reactions, namely Knoevenagel reaction, Michael-type reaction, ring closure, and subsequent aromatization, in one pot has not been previously reported.

## Conclusions

In conclusion, we have disclosed a novel and convenient one-pot synthesis of polysubstituted amino pyrazole analogues *via* multi-component reactions. This catalyst-free reaction proceeded smoothly in good to excellent yields and offered several other advantages including short reaction time, simple experimental workup procedures, and no toxic by-products. The approach to pyrazole systems presented herein avoids the use of catalyst, toxic organic solvent, and anhydrous conditions. This protocol represents a promising green route for the synthesis of this class of compounds.

## Experimental

### Chemicals and apparatus

All chemicals were purchased from Merck or Fluka Chemical Companies and they were used as received. The <sup>1</sup>H NMR (500 MHz, 400 MHz) and <sup>13</sup>C NMR (125 MHz, 100 MHz) spectra were recorded on a Bruker Avance DPX-250, FT-

NMR spectrometer ( $\delta$  in ppm). Tetramethylsailane (TMS) was used as internal standard. The abbreviations used for NMR signals are: s = singlet, d = doublet, t = triplet, q = quartet, and m = multiplet. Melting points were recorded on a Büchi B-545 apparatus in open capillary tubes and are uncorrected.

#### General procedure for the preparation of 5-Amino-1,3-diaryl-1*H*-pyrazole-4-carbonitriles derivatives

Phenyl hydrazine derivative, (1 mmol) aromatic aldehyde (1 mmol), and malono derivative (1 mmol) were added in a 25 ml round-bottomed flask contained water and ethanol (50% v/v) (6 mL), and the resulting mixture was stirred at room temperature. After completion of the reaction (as monitored by TLC), crystals of the product were formed, collected by filtration and then recrystallized from hot ethanol to obtain pure products.

#### Selected spectral data of the products

##### 5-Amino-1,3-diphenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 1)

White powder (0.247 g, 95%), M.P. = 160 – 161 °C,  $\nu_{\max}$  (KBr) 3485, 3341, 3083, 2359, 1599, 1412, 1253, 1126, 1100, 1075 cm<sup>-1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 6.91 (t,  $J$  = 7.3 Hz, 1H), 7.16 (d,  $J$  = 7.6 Hz, 2H), 7.29–7.35 (m, 3H), 7.41 (t,  $J$  = 7.7 Hz, 2H), 7.64 (s, 1H), 7.70 (d,  $J$  = 7.2 Hz, 2H), 7.72 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 112.80, 113.26, 120.58, 126.65, 128.9, 129.05, 129.75, 135.74, 137.81, 145.09, 150.41, 156.50. MS (m/z): 260 (M<sup>+</sup>). Anal.Calcd for C<sub>16</sub>H<sub>12</sub>N<sub>4</sub>: C, 73.83; H, 4.65; N, 21.52%. Found: C, 73.48; H, 4.86; N, 21.72%.

##### 5-Amino-1-phenyl-3-p-tolyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 2)

Pink powder (0.241g, 88%), M.P. = 117–118 °C,  $\nu_{\max}$  (KBr) 3482, 3319, 3095, 2925, 2359, 1598, 1415, 1257, 1127, 1113, 1096 cm<sup>-1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 2.41 (s, 3H), 6.91 (dd,  $J$  = 3.5 Hz and  $J$  = 7.3 Hz, 1H), 7.15 (d,  $J$  = 7.76 Hz, 2H), 7.22 (d,  $J$  = 7.9 Hz, 2H), 7.29–7.33 (m, 2H), 7.59 (d,  $J$  = 7.9 Hz, 2H), 7.70 (s, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 21.90, 104.65, 113.22, 120.44, 126.62, 129.71, 129.77, 132.95, 138.14, 138.97, 145.20, 148.82, 153.20. Anal.Calcd for C<sub>17</sub>H<sub>14</sub>N<sub>4</sub>: C, 74.43; H, 5.14; N, 20.42%. Found: C, 74.88; H, 5.18; N, 20.12%.

##### 5-Amino-3-(2-hydroxyphenyl)-1-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 3)

Yellow powder (0.252g, 96 %), M.P. = 161–162 °C,  $\nu_{\max}$  (KBr) 3583, 3487, 3341, 3102, 2358, 2197, 1602, 1413, 1222, 1192, 1108, 1050 cm<sup>-1</sup>. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz):  $\delta$  (ppm) 6.76 (t,  $J$  = 7.3 Hz, 1H), 6.85–6.90 (m, 2H), 6.96 (d,  $J$  = 7.6 Hz, 2H), 7.14–7.18 (m, 1H), 7.24 (dd,  $J$  = 7.5 Hz and  $J$  = 8.3 Hz, 2H), 7.53 (dd,  $J$  = 1.5 Hz and  $J$  = 7.7 Hz, 1H), 8.14 (s, 1H), 10.38 (s, 1H), 10.52 (s, 1H). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz):  $\delta$  (ppm) 112.60, 116.80, 119.83, 120.25, 121.35, 125.45, 128.17, 130.05, 130.15, 138.13, 145.62, 150.55, 152.30, 156.51. Anal.Calcd for C<sub>16</sub>H<sub>12</sub>N<sub>4</sub>O: C, 69.55; H, 4.38; N, 20.28%. Found: C, 69.48; H, 4.46; N, 20.35%.

##### 5-Amino-3-(4-chlorophenyl)-1-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 4)

White powder (0.279g, 92 %), M.P. = 129–130 °C,  $\nu_{\max}$  (KBr) 3448, 3315, 3074, 2358, 1595, 1414, 1293, 1254, 1133, 1083 cm<sup>-1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 6.93 (t,  $J$  = 7.3 Hz, 1H), 7.15 (d,  $J$  = 7.7 Hz, 2H), 7.29–7.34 (m, 2H), 7.37 (d,  $J$  = 8.4 Hz, 2H), 7.62 (d,  $J$  = 8.4 Hz, 2H), 7.67 (s, 2H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 110.24, 113.29, 120.85, 127.71, 129.26, 129.77, 134.26, 134.44, 136.35, 144.78, 150.21, 155.45. Anal.Calcd for C<sub>16</sub>H<sub>11</sub>ClN<sub>4</sub>: C, 65.20; H, 3.76; N, 19.01%. Found: C, 65.37; H, 3.81; N, 18.95%.

##### 5-Amino-3-(4-nitrophenyl)-1-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 5)

Red powder (0.298 g, 98 %), M.P. = 164–165 °C,  $\nu_{\max}$  (KBr) 3467, 3350, 3102, 2359, 1600, 1415, 1457, 1344, 1256, 1123, 1107, 1095 cm<sup>-1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 6.98 (s, 1H) 7.18 (d,  $J$  = 7.5 Hz, 2H), 7.29–7.34 (m, 2H), 7.73–7.79 (m, 3H), 8.05 (s, 1H), 8.24 (d,  $J$  = 7.6 Hz, 2H). MS (m/z): 305 (M<sup>+</sup>). Anal.Calcd for C<sub>16</sub>H<sub>11</sub>N<sub>5</sub>O<sub>2</sub>: C, 62.95; H, 3.63; N, 22.94%. Found: C, 63.05; H, 3.58; N, 23.03%.

##### 5-Amino-3-(3-nitrophenyl)-1-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 6)

Orange powder (0.292 g, 96 %), M.P. = 129–130 °C,  $\nu_{\max}$  (KBr) 3452, 3324, 3103, 2357, 1594, 1478, 1447, 1344, 1338, 1263, 1147, 1100, 1096 cm<sup>-1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 6.97 (t,  $J$ =7.2 Hz, 1H), 7.18 (d,  $J$ =8.4 Hz, 2H), 7.35 (t,  $J$ =7.5 Hz, 2H), 7.56 (t,  $J$ =7.9 Hz, 1H), 7.74 (s, 1H), 7.89 (s, 1H), 8.01 (d,  $J$ =7.5 Hz, 1H), 8.14 (d,  $J$ =8.0 Hz, 1H), 8.48 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 112.44, 113.42, 121.10, 121.38, 122.98, 129.85, 129.94, 131.80, 134.30, 137.72, 144.27, 149.16, 156.41. Anal.Calcd for C<sub>16</sub>H<sub>11</sub>N<sub>5</sub>O<sub>2</sub>: C, 62.95; H, 3.63; N, 22.94%. Found: C, 62.78; H, 3.77; N, 22.90%.

**5-Amino-3-(2-nitrophenyl)-1-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 7)**

Red powder (0.289 g, 95 %), M.P. = 160–161 °C,  $\nu_{\max}$  (KBr) 3439, 3296, 3024, 2358, 1600, 1497, 1469, 1342, 1333, 1298, 1254, 1163, 1134 cm<sup>−1</sup>. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz):  $\delta$  (ppm) 6.81 (t, *J* = 7.3 Hz, 1H), 7.11 (d, *J* = 7.7 Hz, 2H), 7.25 (t, *J* = 7.6 Hz, 2H), 7.47 (t, *J* = 7.2 Hz, 1H), 7.69 (t, *J* = 7.5 Hz, 1H), 7.95 (d, *J* = 7.5 Hz, 1H), 8.15 (d, *J* = 7.8 Hz, 1H), 8.26 (s, 1H), 10.88 (s, 1H). Anal. Calcd for C<sub>16</sub>H<sub>11</sub>N<sub>5</sub>O<sub>2</sub>: C, 62.95; H, 3.63; N, 22.94 %. Found: C, 63.12; H, 3.55; N, 22.85 %.

**5-Amino-3-(4-cyanophenyl)-1-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 8)**

Yellow powder (0.256 g, 90 %), M.P. = 159–160 °C,  $\nu_{\max}$  (KBr) 3438, 3306, 3279, 2359, 2224, 1593, 1478, 1262, 1159, 1107, 1093 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 6.80 (t, *J* = 7.2 Hz, 1H), 7.12 (d, *J* = 7.6 Hz, 2H), 7.24 (t, *J* = 7.4 Hz, 2H), 7.78–7.81 (m, 4H), 7.87 (s, 1H), 10.73 (s, 1H). Anal. Calcd for C<sub>17</sub>H<sub>11</sub>N<sub>5</sub>: C, 71.57; H, 3.89; N, 24.55 %. Found: C, 71.35; H, 3.70; N, 24.50 %.

**5-Amino-3-(4-isopropylphenyl)-1-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 9)**

Pink powder (0.235 g, 78 %), M.P. = 139–140 °C,  $\nu_{\max}$  (KBr) 3417, 3295, 3102, 2923, 2357, 1600, 1481, 1257, 1125, 1096, 1048 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 1.33 (d, *J* = 6.9 Hz, 6H), 2.94–3.00 (m, 1H), 6.91 (t, *J* = 7.2 Hz, 1H), 7.15 (d, *J* = 7.8 Hz, 2H), 7.27–7.33 (m, 4H), 7.63 (d, *J* = 7.965 Hz, 2H), 7.70 (s, 1H), 8.35 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 24.32, 34.45, 111.28, 113.17, 120.38, 126.69, 127.14, 129.71, 133.39, 137.99, 145.27, 149.32, 149.93, 156.43. Anal. Calcd for C<sub>19</sub>H<sub>18</sub>N<sub>4</sub>: C, 75.47; H, 6.00; N, 18.53 %. Found: C, 75.25; H, 5.78; N, 19.05 %.

**5-Amino-3-(3,4-dimethoxyphenyl)-1-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 10)**

White powder (0.233 g, 73 %), M.P. = 122–123 °C,  $\nu_{\max}$  (KBr) 3432, 3295, 3007, 2939, 2357, 1600, 1476, 1331, 1264, 1236, 1167, 1130, 1018 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 3.93 (s, 3H), 3.99 (s, 3H), 6.86–6.94 (m, 2H), 7.06 (d, *J* = 7.1 Hz, 1H), 7.13 (d, *J* = 8.2 Hz, 2H), 7.30 (t, *J* = 7.4 Hz, 2H), 7.40 (s, 1H), 7.63 (s, 1H), 9.90 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 56.20, 56.23, 113.62, 114.70, 118.87, 118.96, 119.56, 120.43, 131.71, 131.91, 132.85, 133.19, 138.59, 140.46, 150.73, 156.47. Anal. Calcd for C<sub>18</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>: C, 67.49; H, 5.03; N, 17.49 %. Found: C, 67.37; H, 5.10; N, 17.52 %.

**5-Amino-1-phenyl-3-(thiophen-2-yl)-1*H*-pyrazole-4-carbonitrile (Table 1, entry 11)**

Yellow powder (0.234 g, 88 %), M.P. = 140–141 °C,  $\nu_{\max}$  (KBr) 3412, 3325, 3092, 2357, 1600, 1478, 1298, 1264, 1138, 1069 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 6.92 (t, *J* = 7.3 Hz, 1H), 7.05 (dd, *J* = 3.6 Hz and *J* = 4.9 Hz, 1H), 7.12 (d, *J* = 7.4 Hz, 3H), 7.31 (dd, *J* = 5.0 Hz and *J* = 14.1 Hz, 3H), 7.56 (s, 1H), 7.84 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 113.24, 114.21, 120.64, 122.44, 126.33, 126.89, 127.66, 129.76, 132.70, 140.91, 144.86, 155.22. Anal. Calcd for C<sub>14</sub>H<sub>10</sub>N<sub>4</sub>S: C, 63.14; H, 3.78; N, 21.04 %. Found: C, 63.33; H, 3.82; N, 20.88 %.

**5-Amino-3-(5-methylthiophen-2-yl)-1-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 12)**

Yellow powder (0.252 g, 90 %), M.P. = 131–132 °C,  $\nu_{\max}$  (KBr) 3427, 3303, 3102, 2919, 2357, 1600, 1469, 1257, 1230, 1126, 1100, 1070 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 2.53 (s, 3H), 6.68–6.71 (m, 1H), 6.88–6.92 (m, 2H), 7.10 (d, *J* = 7.7 Hz, 2H), 7.28–7.32 (m, 2H), 7.46 (s, 1H), 7.76 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 16.08, 113.15, 114.13, 120.42, 125.86, 126.10, 127.16, 129.71, 133.18, 138.66, 141.38, 145.05, 156.73. Anal. Calcd for C<sub>15</sub>H<sub>12</sub>N<sub>4</sub>S: C, 64.26; H, 4.31; N, 19.98 %. Found: C, 64.37; H, 4.25; N, 20.05 %.

**5-Amino-3-(naphthalene-6-yl)-1-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 13)**

Yellow powder (0.264 g, 93 %), M.P. = 229–230 °C,  $\nu_{\max}$  (KBr) 3403, 3341, 3112, 2358, 1600, 1478, 1252, 1122, 1113, 1082 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 6.87–6.98 (m, 1H), 7.20 (d, *J* = 7.4 Hz, 2H), 7.34 (t, *J* = 7.5 Hz, 2H), 7.50–7.52 (m, 2H), 7.70 (s, 1H), 7.79–7.94 (m, 5H), 8.07 (d, *J* = 8.5 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 113.27, 114.81, 120.66, 123.43, 126.63, 126.83, 126.95, 127.63, 128.28, 128.44, 128.83, 129.77, 130.58, 132.22, 133.98, 137.87, 143.30, 155.97. Anal. Calcd for C<sub>20</sub>H<sub>14</sub>N<sub>4</sub>: C, 77.40; H, 4.55; N, 18.05 %. Found: C, 77.18; H, 4.72; N, 18.13 %.

**5-Amino-1-(4-chlorophenyl)-3-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 14)**

Pink powder (0.261 g, 89 %), M.P. = 134–135 °C,  $\nu_{\max}$  (KBr) 3421, 3318, 3098, 2356, 1597, 1477, 1257, 1135, 1096, 1074 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 7.08 (d, *J* = 8.6 Hz, 2H), 7.25 (d, *J* = 8.5 Hz, 2H), 7.35–7.36 (m, 1H) 7.41 (t, *J* = 7.9 Hz, 2H), 7.55 (s, 1H), 7.68 (d, *J* = 7.7 Hz, 2H), 7.72 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 112.10, 114.32, 125.10, 126.70, 129.08, 129.12,

129.62, 132.32, 135.43, 138.40, 143.70, 155.98. Anal. Calcd for C<sub>16</sub>H<sub>11</sub>ClN<sub>4</sub>: C, 65.20; H, 3.76; N, 19.01 %. Found: C, 64.97; H, 3.87; N, 19.11 %.

**5-Amino-1-(4-bromophenyl)-3-phenyl-1*H*-pyrazole-4-carbonitrile (Table 1, entry 15)**

White powder (0.299 g, 89 %), M.P. = 130–131 °C,  $\nu_{\max}$  (KBr) 3425, 3317, 3114, 2357, 1597, 1480, 1253, 1137, 1094, 1068 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 7.03 (d, *J* = 8.8 Hz, 2H), 7.36 (d, *J* = 7.3 Hz, 1H), 7.39–7.43 (m, 4H), 7.59 (s, 1H), 7.68 (d, *J* = 5.1 Hz, 2H), 7.68 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 112.29, 114.78, 125.65, 126.73, 129.10, 129.16, 130.12, 132.51, 135.41, 138.50, 144.15, 151.78. Anal. Calcd for C<sub>16</sub>H<sub>11</sub>BrN<sub>4</sub>: C, 56.66; H, 3.27; N, 16.52 %. Found: C, 56.97; H, 3.15; N, 16.43 %.

**5-Amino-1-(4-bromophenyl)-3-(naphthalen-1-yl)-1*H*-pyrazole-4-carbonitrile (Table 1, entry 16)**

Yellow powder (0.260 g, 90 %), M.P. = 139–140 °C,  $\nu_{\max}$  (KBr) 3470, 3306, 3082, 2358, 1591, 1480, 1250, 1137, 1096, 1068 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 7.08 (d, *J* = 8.4 Hz, 2H), 7.43 (d, *J* = 8.5 Hz, 2H), 7.51–7.59 (m, 2H), 7.63 (t, *J* = 8.1 Hz, 1H), 7.72 (s, 1H), 7.87 (t, *J* = 6.2 Hz, 2H), 7.92 (d, *J* = 8.0 Hz, 1H), 8.32 (s, 1H), 8.76 (d, *J* = 8.4 Hz, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 112.37, 114.81, 119.02, 124.21, 124.63, 125.87, 126.42, 127.24, 128.12, 128.86, 129.25, 129.75, 130.79, 132.59, 134.44, 138.04, 144.10, 156.32. Anal. Calcd for C<sub>20</sub>H<sub>13</sub>BrN<sub>4</sub>: C, 61.71; H, 3.37; N, 14.39 %. Found: C, 61.55; H, 3.44; N, 14.28 %.

**5-Amino-3-(4-ethoxyphenyl)-1*H*-pyrazole-4-carbonitrile (Table 1, entry 17)**

White powder (0.261 g, 86 %), M.p. = 123–124 °C,  $\nu_{\max}$  (KBr) 3416, 3329, 3102, 2921, 2358, 1602, 1481, 1252, 1126, 1118, 1096 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz):  $\delta$  (ppm) 1.47 (t, *J* = 6.9 Hz, 3H), 4.10 (q, *J* = 6.9 Hz, 2H), 6.88 (t, *J* = 8.0 Hz, 1H), 6.94 (d, *J* = 8.6 Hz, 2H), 7.14 (d, *J* = 8.0 Hz, 2H), 7.29–7.32 (m, 2H), 7.57 (s, 1H), 7.63 (d, *J* = 8.6 Hz, 2H), 7.70 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz):  $\delta$  (ppm) 15.231, 63.98, 112.34, 113.27, 115.108, 120.38, 123.55, 128.16, 129.70, 138.01, 138.32, 138.52, 145.89, 159.99. Anal. Calcd for C<sub>18</sub>H<sub>16</sub>N<sub>4</sub>O: C, 71.04; H, 5.30; N, 18.41 %. Found: C, 71.22; H, 5.16; N, 18.52 %.

**3,3'-(1,4-phenylene)bis(5-amino-1-phenyl-1*H*-pyrazole-4-carbonitrile) (Table 1, entry 18)**

Orange powder (0.420 g, 95 %), M.P. > 230 °C,  $\nu_{\max}$  (KBr) 3422, 3302, 3108, 2357, 1594, 1469, 1254, 1140, 1102, 1055

cm<sup>−1</sup>. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz):  $\delta$  (ppm) 6.76 (t, *J* = 7.6 Hz, 2H) 7.09 (d, *J* = 7.7 Hz, 4H), 7.23 (t, *J* = 7.5 Hz, 4H), 7.65 (d, *J* = 4.2 Hz, 4H), 7.87 (s, 2H), 10.38 (s, 2H). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz):  $\delta$  (ppm) 112.92, 113.86, 119.69, 124.30, 126.75, 130.00, 136.21, 137.06, 146.07, 156.76. MS (*m/z*): 442 (M<sup>+</sup>). Anal. Calcd for C<sub>26</sub>H<sub>18</sub>N<sub>8</sub>: C, 70.58; H, 4.10; N, 25.32 %. Found: C, 70.82; H, 3.95; N, 25.21 %.

**3,3'-(1,3-phenylene)bis(5-amino-1-phenyl-1*H*-pyrazole-4-carbonitrile) (Table 1, entry 19)**

Yellow powder (0.406 g, 92 %), M.P. > 230 °C,  $\nu_{\max}$  (KBr) 3482, 3305, 3076, 2357, 1592, 1480, 1252, 1133, 1101, 1072 cm<sup>−1</sup>. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 500 MHz):  $\delta$  (ppm) 6.77 (t, *J* = 7.2 Hz, 2H), 7.11 (d, *J* = 7.9 Hz, 4H), 7.24 (t, *J* = 7.6 Hz, 4H), 7.41 (t, *J* = 7.6 Hz, 1H), 7.60 (d, *J* = 7.6 Hz, 2H), 7.86 (s, 1H), 7.92 (s, 2H), 10.38 (s, 2H). <sup>13</sup>C NMR (DMSO-*d*<sub>6</sub>, 125 MHz):  $\delta$  (ppm) 112.94, 113.70, 119.72, 121.80, 123.95, 125.81, 129.84, 130.02, 137.09, 137.13, 146.13, 156.44. MS (*m/z*): 442 (M<sup>+</sup>). Anal. Calcd for C<sub>26</sub>H<sub>18</sub>N<sub>8</sub>: C, 70.58; H, 4.10; N, 25.32 %. Found: C, 70.45; H, 4.17; N, 25.39 %.

**Diethyl 3,3'-(1,4-phenylene)bis(5-amino-1-phenyl-1*H*-pyrazole-4-carboxylate) (Table 1, entry 20)**

Yellow powder (0.466 g, 87 %), M.P. > 230 °C,  $\nu_{\max}$  (KBr) 3486, 3348, 3108, 2996, 1722, 1598, 1475, 1251, 1130, 1121, 1079 cm<sup>−1</sup>. <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 400 MHz):  $\delta$  (ppm) 1.43 (t, *J* = 7.2 Hz, 6H), 4.42 (q, *J* = 7.2 Hz, 4H), 6.96 (t, *J* = 7.2 Hz, 2H), 7.18 (d, *J* = 7.6 Hz, 4H), 7.34 (t, *J* = 8.0 Hz, 4H), 7.71 (s, 2H), 7.79 (d, *J* = 8.4 Hz, 2H), 8.04 (d, *J* = 8.4 Hz, 2H), 8.25 (s, 2H). MS (*m/z*): 536 (M<sup>+</sup>). Anal. Calcd for C<sub>30</sub>H<sub>28</sub>N<sub>6</sub>O<sub>4</sub>: C, 67.15; H, 5.26; N, 15.66 %. Found: C, 67.23; H, 5.33; N, 15.54 %.

**Methyl 5-amino-1,3-diphenyl-1*H*-pyrazole-4-carboxylate (Table 1, entry 21)**

White powder (0.272 g, 93 %), M.p. = 161–162 °C,  $\nu_{\max}$  (KBr) 3463, 3312, 3104, 2985, 1719, 1600, 1481, 1254, 1134, 1118, 1083 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  (ppm) 3.68 (s, 3H), 6.93 (t, *J* = 7.2 Hz, 1H), 7.16 (d, *J* = 8 Hz, 2H), 7.29–7.37 (m, 3H), 7.42 (t, *J* = 7.4 Hz, 2H), 7.61 (s, 1H), 7.68 (s, 1H), 7.70 (d, *J* = 7.6 Hz, 2H). MS (*m/z*): 293 (M<sup>+</sup>). Anal. Calcd for C<sub>18</sub>H<sub>13</sub>N<sub>3</sub>O<sub>2</sub>: C, 71.28; H, 4.32; N, 13.85 %. Found: C, 70.94; H, 4.54; N, 13.78 %.

**Ethyl 5-amino-1,3-diphenyl-1*H*-pyrazole-4-carboxylate (Table 1, entry 22)**

White powder (0.292 g, 95 %), M.p. = 163–164 °C,  $\nu_{\max}$  (KBr) 3459, 3316, 3078, 2988, 1718, 1593, 1479, 1256, 1128, 1114, 1106 cm<sup>−1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  (ppm) 1.36

(t,  $J = 7.6$  Hz, 3H), 4.8 (q,  $J = 7.6$  Hz, 2H), 6.94 (t,  $J = 7.2$  Hz, 1H), 7.17 (d,  $J = 7.6$  Hz, 2H), 7.32–7.37 (m, 3H), 7.42 (t,  $J = 7.4$  Hz, 2H), 7.62 (s, 1H), 7.66 (s, 1H), 7.71 (d,  $J = 7.2$  Hz, 2H). MS ( $m/z$ ): 307 (M $+$ ). Anal. Calcd for C<sub>19</sub>H<sub>15</sub>N<sub>3</sub>O<sub>2</sub>: C, 71.91; H, 4.76; N, 13.24 %. Found: C, 71.38; H, 4.89; N, 13.45 %.

*Methyl 5-amino-3-(4-nitrophenyl)-1-phenyl-1*H*-pyrazole-4-carboxylate (Table 1, entry 23)*

Red powder (0.321 g, 95 %), M.p. = 162–163 °C,  $\nu_{\text{max}}$  (KBr) 3452, 3339, 3110, 2989, 1723, 1600, 1482, 1497, 1348, 1254, 1133, 1120, 1081 cm<sup>-1</sup>. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  (ppm) 3.80 (s, 3H), 6.98 (t,  $J = 7.4$  Hz, 1H), 7.18 (d,  $J = 7.6$  Hz, 2H), 7.36 (t,  $J = 4$  Hz, 2H), 7.73 (s, 1H), 7.80 (d,  $J = 8.8$  Hz, 2H), 8.02 (s, 1H), 8.25 (d,  $J = 8.8$  Hz, 2H). MS ( $m/z$ ): 338 (M $+$ ). Anal. Calcd for C<sub>18</sub>H<sub>12</sub>N<sub>4</sub>O<sub>4</sub>: C, 62.07; H, 3.47; N, 16.09 %. Found: C, 62.50; H, 3.63; N, 15.79 %.

*5'-Amino-2-oxo-1'-phenyl-1',2'-dihydropyro[*indoline-3,3'*-pyrazole]-4-carbonitrile (10, Scheme 4)*

Yellow powder M.p. = 214–216 <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz)  $\delta$  (ppm): 88.92 (s, 1H), 6.96 (d,  $J = 7.75$  Hz, 1H), 7.09–7.127 (m, 1H), 7.15 (d,  $J = 7.56$ , 1H), 7.27 (dd,  $J = 4.0$  Hz,  $J = 8.0$  Hz, 1H), 7.39–7.42 (m, 4H), 7.68 (d,  $J = 7.5$  Hz, 1H), 8.26 (s, 1H), 12.74 (s, 1H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz)  $\delta$  (ppm): 103.84, 110.70, 114.88, 119.60, 122.54, 123.077, 123.81, 127.52, 128.48, 129.86, 138.55, 141.72, 142.96, 155.22, 164.09.

**Acknowledgments** The authors thank Persian Gulf University Research Councils for the financial support of this work.

## References

- Hasaninejad A, Zare A, Shekouhy M (2011) Sulfuric acid-modified PEG-6000 (PEG-OSO<sub>3</sub>H): an efficient, bio-degradable and reusable polymeric catalyst for the solvent-free synthesis of poly-substituted quinolines under microwave irradiation. Green Chem 13:958–964. doi:[10.1039/c0gc00953a](https://doi.org/10.1039/c0gc00953a)
- Hasaninejad A, Zare A, Shekouhy M (2010) Catalyst-free one-pot four component synthesis of polysubstituted imidazoles in neutral. Ionic liquid 1-butyl-3-methylimidazolium bromide. J Comb Chem 12:844–849. doi:[10.1021/cc100097m](https://doi.org/10.1021/cc100097m)
- Hasaninejad A, Zare A, Mohammadizadeh MR, Shekouhy M (2010) Lithium bromide as an efficient, green, and inexpensive catalyst for the synthesis of quinoxaline derivatives at room temperature. Green Chem Lett Rev 3:143–148. doi:[10.1080/17518251003619192](https://doi.org/10.1080/17518251003619192)
- Hasaninejad A, Zare A, Shekouhy M (2010) Highly efficient synthesis of triazolo[1,2-*a*]indazole-triones and novel spiro triazolo[1, 2-*a*]indazole-tetraones under solvent-free conditions. Tetrahedron 67:390–400. doi:[10.1016/j.tet.2010.11.029](https://doi.org/10.1016/j.tet.2010.11.029)
- Hasaninejad A, Zare A, Zolfogol MA, Shekouhy M (2009) Zirconium Tetrakis(dodecyl Sulfate) [Zr(DS)<sub>4</sub>] as an efficient Lewis acid-surfactant combined catalyst for the synthesis of quinoxaline derivatives in aqueous media. Synth Commun 39:569–579. doi:[10.1080/00397910802406737](https://doi.org/10.1080/00397910802406737)
- Hasaninejad A, Golzar N, Shekouhy M, Zare A (2011) Diversity-oriented synthesis of novel 2*t*-aminospiro[11*H*-indenol[1,2-*b*]quinoxaline-11,4*t* – [4*H*]pyran] derivatives via a one-pot four-component reaction. Helv Chim Acta 94:2289–2294. doi:[10.1002/hcl.201100201](https://doi.org/10.1002/hcl.201100201)
- Hasaninejad A, Shekouhy M, Zare A (2012) Silica nanoparticles efficiently catalyzed synthesis of quinolines and quinoxalines. Catal Sci Technol 2:201–214. doi:[10.1039/c1cy00332a](https://doi.org/10.1039/c1cy00332a)
- Anzai K, Furuse M, Yoshida A, Matsuyama A, Moritake T, Tsuboi K, Ikota N (2004) In vivo radioprotection of mice by 3-methyl-1-phenyl-2-pyrazolin-5-one (Edaravone; Radicut), a clinical drug. J Radiat Res 45:319–323
- Yet L (2008) in Comprehensive heterocyclic chemistry III. In: Katritzky AR, Ramsden CA, Scriven EFV, Taylor RJK (eds.). Elsevier, Oxford 4:1
- Daidone G, Maggio B, Plescia S, Raffa D, Musiu C, Milia C, Perra G, Marongiu ME (1998) Antimicrobial and antineoplastic activities of new 4-diazopyrazole derivatives. Eur J Med Chem 33:375–382. doi:[10.1016/S0223-5234\(98\)80004-4](https://doi.org/10.1016/S0223-5234(98)80004-4)
- Taylor EC, Patel H, Kumar H (1992) Synthesis of pyrazolo 3,4-dypyrimidine analogues of the potent agent N-4-2-2-amino-4 3H-oxo-7H-pyrrolo 2,3-dypyrimidin-5-yl ethylbenzoyl-L-glutamic acid (LY231514). Tetrahedron 48:8089–8100. doi:[10.1016/S0040-4020\(01\)80479-8](https://doi.org/10.1016/S0040-4020(01)80479-8)
- Akbas E, Berber I, Sener A, Hasanov B (2005) Synthesis and antibacterial activity of 4-benzoyl-1-methyl-5-phenyl-1*H*-pyrazole-3-carboxylic acid and derivatives. IL Farmaco 60:23–26. doi:[10.1016/j.farmac.2004.09.003](https://doi.org/10.1016/j.farmac.2004.09.003)
- Tanitame A, Oyamada Y, Ofuji K (2004) Design, synthesis and structure-activity relationship studies of novel indazole analogues as DNA gyrase inhibitors with Gram-positive antibacterial activity. Bioorg Med Chem Lett 14:2857–2862. doi:[10.1016/j.bmcl.2004.03.044](https://doi.org/10.1016/j.bmcl.2004.03.044)
- Bekhita AA, Abdel-Aziem T (2004) Design, synthesis and biological evaluation of some pyrazole derivatives as anti-inflammatory-antimicrobial agents. Bioorg Med Chem 12:1935–1945. doi:[10.1016/j.bmc.2004.01.037](https://doi.org/10.1016/j.bmc.2004.01.037)
- Stahman MA, Huebner CF, Link KP (1941) Studies on the hemorrhagic sweet clover disease: v. identification and synthesis of hemorrhagic agent. J Biol Chem 138:513–527
- Nauduri D, Reddy GB (1998) Antibacterials and antimycotics: part 1: synthesis and activity of 2-pyrazoline derivatives. Chem Pharm Bull 46:1254–1260
- Foks H, Pancechowska-Ksepko D, Kedzia A, Zwolska Z, Janowiec M, Augustynowicz-Kopeć E (2005) Synthesis and antibacterial activity of 1*H*-pyrazolo[3,4-*b*]pyrazine and -pyridine derivatives. IL Farmaco 60:513–517. doi:[10.1016/j.farmac.2005.05.002](https://doi.org/10.1016/j.farmac.2005.05.002)
- Dardari Z, Lemrani M, Sebban A, Bahloul A, Hassar M, Kitane S, Berrada M, Boudouma B (2006) Ethyl 5-amino-1-(4-chloro-2-nitro-phenyl)-1*H*-pyrazole-4-carboxyl-ate. Arch Pharm (Weinheim Ger) 339:291–298. doi:[10.1107/S1600536809000488](https://doi.org/10.1107/S1600536809000488)
- Gilbert AM, Failli A, Shumsky J, Yang Y (2006) Pyrazolidine-3,5-diones and 5-hydroxy-1*H*-pyrazol-3(2*H*)-ones, Inhibitors of UDP-N-acetylenolpyruvyl glucosamine reductase. J Med Chem 49:1202–1204. doi:[10.1021/jm060499t](https://doi.org/10.1021/jm060499t)
- Tanitame A, Oyamada Y, Ofugi K, Fujimoto M, Iwai N, Hiyama Y, Suzuki KM, Yamagishi J (2004) Synthesis and antibacterial activity of a novel series of potent DNA gyrase inhibitors. Pyrazole derivatives. J Med Chem 47:3693–3696. doi:[10.1021/jm030394f](https://doi.org/10.1021/jm030394f)
- Badawey AM, El-Ashmawy IM (1998) Nonsteroidal antiinflammatory agents - part 1: antiinflammatory, analgesic and antipyretic activity of some new 1-(pyrimidin-2-yl)-3-pyrazolin-5-ones and 2-

- (pyrimidin-2-yl)-1,2,4,5,6,7-hexahydro-3*H*-indazol-3-ones. *Eur J Med Chem* 33:349–361. doi:[10.1016/S0223-5234\(98\)80002-0](https://doi.org/10.1016/S0223-5234(98)80002-0)
22. Tewari AK, Mishra A (2001) Synthesis and anti-inflammatory activities of N<sup>4</sup>, N<sup>5</sup>-disubstituted-3-methyl-1*H*-pyrazolo[3,4-c]pyridazines. *Bioorg Med Chem* 9:715–718. doi:[10.1016/S0968-0896\(00\)00285-6](https://doi.org/10.1016/S0968-0896(00)00285-6)
  23. Wise LD, Butler DE, Dewald HA, Lustgarten DM, Pattison IC, Schweiss DN, Coughenour LL, Downs DA, Heffner TG, Pugsley TA (1987) 1,3-Dialkyl-4-(iminoaryl methyl)-1*H*-pyrazol-5-ols. A series of novel potential antipsychotic agents. *J Med Chem* 30:1807–1812. doi:[10.1021/jm00393a021](https://doi.org/10.1021/jm00393a021)
  24. Gursoy SA, Demirayak G, Capan K (2000) Synthesis and preliminary evaluation of new 5-pyrazolinone derivatives as analgesic agents. *Eur J Med Chem* 35:359–364. doi:[S0223-5234\(00\)001173-FLA](https://doi.org/S0223-5234(00)001173-FLA)
  25. Bailey DM, Hansen PE, Hlavac AG, Baizman ER, Pearl J, Defelice AF, Feigenson ME (1985) 3,4-Diphenyl-1*H*-pyrazole-1-propanamine antidepressants. *J Med Chem* 28:256–260. doi:[10.1021/jm00380a020](https://doi.org/10.1021/jm00380a020)
  26. Özdemir Z, Kandilci HB, Gümüsöl B, Calis Ü, Bilgin AA (2007) Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-furyl)-pyrazoline derivatives. *Eur J Med Chem* 42:373–379. doi:[10.1016/j.ejmech.2006.09.006](https://doi.org/10.1016/j.ejmech.2006.09.006)
  27. Menozzi G, Mosti L, Schenone P, D-Amico M, Filippelli A, Rossi F (1992) 4*H*-thieno[3,4-c]pyrazole derivatives with anti-inflammatory, analgesic, antipyretic and platelet antiaggregating activities. *Farmaco* 47:1495–1511
  28. Rathelot P, Azas N, El-Kashef H, Delmas F (2002) 1,3-Diphenylpyrazoles: synthesis and antiparasitic activities of azomethine derivatives. *Eur J Med Chem* 37:671–679. doi:[10.1016/S0223-5234\(02\)01388-0](https://doi.org/S0223-5234(02)01388-0)
  29. Bernardino AMR, Gomes AO, Charret KS, Freitas ACC (2006) Synthesis and leishmanicidal activities of 1-(4-X-phenyl)-N-[ (4-Y-phenyl)methylene]-1*H*-pyrazole-4-carbohydrazides. *Eur J Med Chem* 41:80–87. doi:[10.1016/j.ejmech.2005.10.007](https://doi.org/10.1016/j.ejmech.2005.10.007)
  30. Katiyar SB, Srivastava K, Purib SK, Chauhana PMS (2005) Synthesis of 2-[3,5-substituted pyrazol-1-yl]-4,6-trisubstituted triazine derivatives as antimalarial agents. *Bioorg Med Chem Lett* 15: 4957–4960. doi:[10.1016/j.bmcl.2005.08.023](https://doi.org/10.1016/j.bmcl.2005.08.023)
  31. Farag AM, Ali KA, Mayhoub AS, Abdalla TM, Amr AE, Abdel-Hafez N, Abdalla MM (2010) Design, synthesis and structure-activity relationship study of novel pyrazole-based heterocycles as potential antitumor agents. *Eur J Med Chem* 45:5887–5898. doi:[10.1016/j.ejmech.2010.09.054](https://doi.org/10.1016/j.ejmech.2010.09.054)
  32. Moukha-Chafiq O, Taha ML, Lazrek HB, Vasseur JJ (2002) Synthesis and biological activity of some 4-substituted 1-[1-(2,3-dihydroxy-1-propoxy)methyl-1,2,3-triazol-(4 & 5)-ylmethyl]-1*H*-pyrazolo[3,4-*d*]pyrimidines. *IL Farmaco* 57:27–32. doi:[10.1016/S0014-827X\(01\)01152-1](https://doi.org/10.1016/S0014-827X(01)01152-1)
  33. Allen SH, Johns BA, Gudmundsson KS, Freeman GA (2006) Synthesis of C-6 substituted pyrazolo[1,5-*a*]pyridines with potent activity against herpesviruses. *Bioorg Med Chem* 14:944–954. doi:[10.1016/j.bmcl.2005.09.015](https://doi.org/10.1016/j.bmcl.2005.09.015)
  34. He FQ, Liu XH, Wang BL, Li ZM (2008) Synthesis and biological activities of novel bis-heterocyclic pyrrodiazole derivatives. *Heteroatom Chemistry* 19:21–27. doi:[10.1002/hc.20369](https://doi.org/10.1002/hc.20369)
  35. Frinkelstein BL, Strok CJ (1997) Synthesis and insecticidal activity of novel pyrazole methanesulfonates. *J Pestic Sci* 50:324–328. doi:[10.1002/\(SICI\)1096-9063\(199708\)50:3<324::AID-PSCI324>3.0.CO;2-1](https://doi.org/10.1002/(SICI)1096-9063(199708)50:3<324::AID-PSCI324>3.0.CO;2-1)
  36. Parlow JJ (1998) Synthesis of pyrazolecarbonylaminopyridinecarboxamides as herbicides. *J Heterocycl Chem* 35:1493–1499. doi:[10.1002/jhet.5570350646](https://doi.org/10.1002/jhet.5570350646)
  37. Halcrow MA (2009) Pyrazoles and pyrazolides—flexible synthons in self-assembly. *Dalton Trans* 2059–2073. doi:[10.1039/B815577A](https://doi.org/10.1039/B815577A)
  38. Singer RA, Dore M, Sieser JE, Berliner MA (2006) Development of nonproprietary phosphine ligands for the Pd-catalyzed amination reaction. *Tetrahedron Lett* 47:3727–3731. doi:[10.1016/j.tetlet.2006.03.132](https://doi.org/10.1016/j.tetlet.2006.03.132)
  39. Kane JL, Hirth BH, Laing O, Gourlie BB, Nahill S, Barsomiam G (2003) Ureas of 5-aminopyrazole and 2-aminothiazole inhibit growth of gram-positive bacteria. *Bioorg Med Chem Lett* 13: 4463–4466. doi:[10.1016/j.bmcl.2003.09.013](https://doi.org/10.1016/j.bmcl.2003.09.013)
  40. Kumar V, Aggarwal R, Tyagi P, Singh SP (2005) Synthesis and antibacterial activity of some new 1-heteraryl-5-amino-4-phenyl-3-trifluoromethylpyrazoles. *Eur J Med Chem* 40:922–927. doi:[10.1016/j.ejmech.2005.03.021](https://doi.org/10.1016/j.ejmech.2005.03.021)
  41. Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Doctor S, Graneto MJ, Lee LF, Malecha JW, Miyashiro JM, Rogers RS, Rogier DJ, Yu SS, Anderson GD, Burton EG, Cogburn JN, Gregory SA, Koboldt CM, Perkins WE, Seibert K, Veenhuizen AW, Zhang YY, Isackson PC (1997) Synthesis and biological evaluation of the 1,5-diarylpypyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1*H*-pyrazol-1-yl]benzenesulfonamide (SC-58635, celecoxib). *J Med Chem* 40:1347–1365. doi:[10.1021/jm960803q](https://doi.org/10.1021/jm960803q)
  42. Terrett NK, Bell AS, Brown D, Ellis P (1996) Sildenafil (VIAGRA<sup>TM</sup>), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction. *Bioorg Med Chem Lett* 6:1819–1824. doi:[10.1016/0960-894X\(96\)00323-X](https://doi.org/10.1016/0960-894X(96)00323-X)
  43. Guzman-Perez A, Webster RT, Allen MC, Brown JA, Buchholz AR, Cook ER, Day WW, Hamanaka ES, Kennedy SP, Knight DR, Kowalczyk PJ, Marala RB, Mularski CJ, Novomisle WA, Ruggeri RB, Tracey WR, Hill RJ (2001) Discovery of zoniporide: A potent and selective sodium-hydrogen exchanger type 1 (NHE-1) inhibitor with high aqueous solubility. *Bioorg Med Chem Lett* 11:803–807. doi:[10.1016/S0960-894X\(01\)00059-2](https://doi.org/10.1016/S0960-894X(01)00059-2)
  44. Kordik CP, Luo C, Zanoni BC, Lovenberg TW, Wilson SJ, Vaidya AH, Cooke JJ, Rosenthal DI, Reitz AB (2001) Pyrazolecarboxamide human neuropeptide Y5 receptor ligands with in vivo antifeedant activity. *Bioorg Med Chem Lett* 11:2287–2290. doi:[10.1016/S0960-894X\(01\)00449-8](https://doi.org/10.1016/S0960-894X(01)00449-8)
  45. Genin MJ, Biles C, Keiser BJ, Poppe SM, Swaney SM, Tarpley WG, Yagi Y, Romero DL (2000) Novel 1,5-diphenylpyrazole non-nucleoside HIV-1 reverse transcriptase inhibitors with enhanced activity versus the delavirdine-resistant P236L mutant: lead identification and SAR of 3- and 4-substituted derivatives. *J Med Chem* 43:904–909. doi:[10.1021/jm990383f](https://doi.org/10.1021/jm990383f)
  46. Hanzlowsky A, Jelencic B, Recnik S, Svete J, Golobic A, Stanovnik B (2003) Regioselective synthesis of ethyl pyrazolecarboxylates from ethyl 3-[(dimethylamino)methylidene]pyruvate and diethyl 3-[(dimethylamino)methylidene]-2-oxosuccinate. Isolation of ethyl 4,5-dihydro-1-heteraryl-5-hydroxy-1*H*-pyrazole-5-carboxylates as stable intermediates in the pyrazole ring formation. *J Heterocycl Chem* 40:487–498. doi:[10.1002/jhet.5570400313](https://doi.org/10.1002/jhet.5570400313)
  47. Varvounis G, Fiamegos Y, Pilidis G (2004) Pyrazol-3-ones. Part II: reactions of the ring atoms. *Adv Heterocycl Chem* 87:141–272
  48. Salaheldin AM, Oliveira-Campos AMF, Rodrigues LM (2007) N-Bromosuccinimide assisted oxidation of 5-aminopyrazoles: formation of bis diazenylderivatives. *Tetrahedron Lett* 48:8819–8822. doi:[10.1016/j.tetlet.2007.10.079](https://doi.org/10.1016/j.tetlet.2007.10.079)
  49. Varvounis G, Fiamegos Y, Pilidis G (2007) Pyrazol-3-ones. Part III: reactivity of the ring substituents. *Adv Heterocycl Chem* 95:27–141
  50. Fustero S, Simon-Fuentes A, Sanz-Cervera JF (2009) Recent advances in the synthesis of pyrazoles. *Org Prep Proced Int* 41: 253–290. doi:[10.1080/00304940903077832](https://doi.org/10.1080/00304940903077832)
  51. Heller ST, Natarajan SR (2006) 1,3-Diketones from acid chlorides and ketones: a rapid and general one-pot synthesis of pyrazoles. *Org Lett* 8:2675–2678. doi:[10.1021/o1060570p](https://doi.org/10.1021/o1060570p)

52. Aggarwal VK, Vicente J, Bonnert RV (2003) A novel one-pot method for the preparation of pyrazoles by 1,3-dipolar cycloadditions of diazo compounds generated in situ. *J Org Chem* 68:5381–5383. doi:[10.1021/jo0268409](https://doi.org/10.1021/jo0268409)
53. Martin R, Rivero MR, Buchwald SL (2006) Domino Cu-catalyzed C–N coupling/hydroamidation: a highly efficient synthesis of nitrogen heterocycles. *Angew Chem Int Ed Engl* 45:7079–7082. doi:[10.1002/anie.200602917](https://doi.org/10.1002/anie.200602917)
54. Neumann JJ, Suri M, Glorius F (2010) Efficient synthesis of pyrazoles: oxidative C–C/N–N bond-formation cascade. *Angew Chem Int Ed* 49:903–907. doi:[10.1002/anie.201002389](https://doi.org/10.1002/anie.201002389)
55. Antilla JC, Baskin JM, Barde TE, Buchwald SL (2004) Copper-diamine-catalyzed N-arylation of pyrroles, pyrazoles, indazoles, imidazoles, and triazoles. *J Org Chem* 69:5578–5587. doi:[10.1021/jo049658b](https://doi.org/10.1021/jo049658b)
56. Cristau HJ, Cellier PP, Spindler JF, Taillefer M (2004) Mild conditions for copper-catalysed N-arylation of pyrazoles. *Eur J Org Chem* 2004:695–709. doi:[10.1021/jo049658b](https://doi.org/10.1021/jo049658b)
57. Mukherjee A, Sarkar A (2004) Pyrazole-tethered arylphosphine ligands for Suzuki reactions of aryl chlorides: how important is chelation? *Tetrahedron Lett* 45:9525–9528. doi:[10.1016/j.tetlet.2004.11.016](https://doi.org/10.1016/j.tetlet.2004.11.016)
58. Zhu L, Guo P, Li G, Lan J, Xie R, You J (2007) Simple copper salt-catalyzed N-arylation of nitrogen-containing heterocycles with aryl and heteroaryl halides. *J Org Chem* 72:8535–8538. doi:[10.1021/jo0712289](https://doi.org/10.1021/jo0712289)
59. Xi Z, Liu F, Zhou Y, Chen W (2008) CuI/L (L=pyridine-functionalized 1,3-diketones) catalyzed C–N coupling reactions of aryl halides with NH-containing heterocycles. *Tetrahedron* 64:4254–4259. doi:[10.1016/j.tet.2008.02.082](https://doi.org/10.1016/j.tet.2008.02.082)
60. Goikhman R, Jacques TL, Sames D (2009) C–H bonds as ubiquitous functionality: a general approach to complex arylated pyrazoles via sequential regioselective C-arylation and N-alkylation enabled by SEM-group transposition. *J Am Chem Soc* 131:3042–3048. doi:[10.1021/ja8096114](https://doi.org/10.1021/ja8096114)
61. Hasaninejad A, Shekouhy M, Golzar N, Zare A, Doroodmand MM (2011) Silica bonded n-propyl-4-aza-1-azoniabicyclo[2.2.2]octane chloride (SB-DABCO): a highly efficient, reusable and new heterogeneous catalyst for the synthesis of 4 H -benzo[b] pyran derivatives. *Appl Catal A: General* 402:11–22. doi:[10.1016/j.apcata.2011.04.012](https://doi.org/10.1016/j.apcata.2011.04.012)
62. Aziz SI, Kandeel ZE, Husein MM, El-Gohary S, El-Maged EIA (1995) Activated nitriles in heterocyclic synthesis: Novel syntheses of 3H-1,2,4-triazolo-[1,5-a]pyridine derivatives. *Heterocycl Chem* 6:319–323. doi:[10.1002/hc.520060408](https://doi.org/10.1002/hc.520060408)
63. Verma D, Mobin S, Namboothiri INN (2011) Highly selective synthesis of pyrazole and spiropyrazoline phosphonates via base-assisted reaction of the Bestmann\_Ohira reagent with Enones. *J Org Chem* 76:4764–4770. doi:[10.1021/jo200582z](https://doi.org/10.1021/jo200582z)
64. Balachandran KS, Bhatnagar I, George MV (1968) Oxidation by metal oxides. IV. Oxidation of organic compounds using nickel peroxide. *J Org Chem* 33:3891–3895. doi:[10.1021/jo01274a043](https://doi.org/10.1021/jo01274a043)
65. Huang YR, Katzenellenbogen JA (2000) Regioselective synthesis of 1,3,5-triaryl-4-alkylpyrazoles: novel ligands for the estrogen receptor. *Org Lett* 2:2833–2836. doi:[10.1021/ol0062650](https://doi.org/10.1021/ol0062650)
66. Jung ME, Min SJ, Houk KN, Ess D (2004) Synthesis and relative stability of 3,5-diacyl-4,5-dihydro-1 H-pyrazoles prepared by dipolar cycloaddition of enones and  $\alpha$ -diazoketones. *J Org Chem* 69:9085–9089. doi:[10.1021/jo048741w](https://doi.org/10.1021/jo048741w)